The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

A new study by researchers at Karolinska Institutet and Karolinska University Hospital shows that patients diagnosed with the ...

Furthermore, Gal-9 was cytotoxic for chemoresistant Sc-1 cells (Sc-1-RES), which were even more sensitive toward Gal-9 treatment than the parental cells (Sc-1-PAR). Thus, Gal-9 potently induced cell ...

Peripheral blood stem cells were collected during salvage chemotherapy or mobilization chemotherapy with etoposide as we previously reported for patients with primary CNS lymphoma (16). The target ...

B-cell lymphomas, which tend to be nodal based, are the more common type, and only rarely have cutaneous manifestations. In contrast, however, T-cell lymphomas commonly manifest in the skin.

Media Contact: Kristen Ingram, (650) 467-6800 Advocacy Contact: Catherine Creme Henry, (202) 258-8228 Investor Contacts: Loren Kalm, (650) 225-3217 Bruno Eschli, +41 61 687 5284 ...

Background: Dose-adjusted EPOCH-R (DA-EPOCH-R) has demonstrated efficacy in aggressive B-cell lymphomas, yet comprehensive real-world data from multiple centers remains limited. We conducted a ...

Genmab A/S (Nasdaq: GMAB) today announced new results from the Phase 1b/2 EPCORE® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging ...

A Phase 1 study for C-CAR039 was conducted in China for the treatment of patients with B-cell non-Hodgkin lymphoma (predominantly LBCL).3 Johnson & Johnson is also evaluating the safety and ...

Cutaneous T-cell lymphomas (CTCLs) are rare, usually refractory, and sometimes fatal diseases. Patients presenting with advanced-stage CTCL usually exhibit poor long-term survival outcomes. Only very ...

Neurons talk to one another using electricity. If you could hear these impulses, they might sound like constant, rapid-fire chatter all over the nervous system. Heart muscle cells do something ...